{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:12:10Z","timestamp":1762164730482,"version":"build-2065373602"},"reference-count":23,"publisher":"Walter de Gruyter GmbH","issue":"11-12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Carbonic anhydrase IX (CAIX) is known to be overexpressed in various tumors and plays a significant role in tumor development and progression. A series of 3-sulfonamide benzoate derivatives with a 7-membered azepane ring were synthesized and evaluated for their CAIX inhibitory activities. Most of the synthesized compounds successfully inhibited CAIX activities, exhibiting IC\n                    <jats:sub>50<\/jats:sub>\n                    values in the low nanomolar range. The most potent CAIX inhibitor was compound\n                    <jats:bold>26<\/jats:bold>\n                    , with an IC\n                    <jats:sub>50<\/jats:sub>\n                    of 19\u202fnM. A structure-activity relationship analysis of the synthesized compounds was conducted, and molecular docking revealed strong coordination with the catalytic Zn\n                    <jats:sup>2+<\/jats:sup>\n                    metal, hydrophobic interactions of the azepane ring with a hydrophobic pocket, and \u03c0-stacking interactions of the aryl ring with an aromatic surface. The three most active analogues (\n                    <jats:bold>8<\/jats:bold>\n                    ,\n                    <jats:bold>16<\/jats:bold>\n                    , and\n                    <jats:bold>26<\/jats:bold>\n                    ) were further tested for their antiproliferative activities in the NCI-60 human tumor cell lines screen. Notably, compound\n                    <jats:bold>16<\/jats:bold>\n                    (CAIX, IC\n                    <jats:sub>50<\/jats:sub>\n                    \u00a0=\u00a0310\u202fnM) demonstrated potent growth inhibitory effects against several cancer cell lines.\n                  <\/jats:p>","DOI":"10.1515\/znc-2024-0224","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T13:04:36Z","timestamp":1740747876000},"page":"763-767","source":"Crossref","is-referenced-by-count":0,"title":["Design and synthesis of 3-(azepan-1-ylsulfonyl)-\n                    <i>N<\/i>\n                    -aryl benzamide derivatives as potent carbonic anhydrase IX inhibitors with anticancer activities"],"prefix":"10.1515","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3232-0979","authenticated-orcid":false,"given":"Mohammad A.","family":"Khanfar","sequence":"first","affiliation":[{"name":"College of Pharmacy , 101686 Alfaisal University , Al Takhassusi Rd , Riyadh 11533 , Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Saleh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Pharmacy , The University of Jordan , P.O Box\u00a013140 , Amman 11942 , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"2025110310023745384_j_znc-2024-0224_ref_001","doi-asserted-by":"crossref","unstructured":"Supuran, CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023\u201332. https:\/\/doi.org\/10.1042\/bcj20160115.","DOI":"10.1042\/BCJ20160115"},{"key":"2025110310023745384_j_znc-2024-0224_ref_002","doi-asserted-by":"crossref","unstructured":"Imtaiyaz Hassan, M, Shajee, B, Waheed, A, Ahmad, F, Sly, WS. Structure, function and applications of carbonic anhydrase isozymes. Bioorg Med Chem 2013;21:1570\u201382. https:\/\/doi.org\/10.1016\/j.bmc.2012.04.044.","DOI":"10.1016\/j.bmc.2012.04.044"},{"key":"2025110310023745384_j_znc-2024-0224_ref_003","doi-asserted-by":"crossref","unstructured":"Supuran, CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expet Opin Drug Discov 2017;12:61\u201388. https:\/\/doi.org\/10.1080\/17460441.2017.1253677.","DOI":"10.1080\/17460441.2017.1253677"},{"key":"2025110310023745384_j_znc-2024-0224_ref_004","doi-asserted-by":"crossref","unstructured":"Waheed, A, Sly, WS. Carbonic anhydrase XII functions in health and disease. Gene 2017;623:33\u201340. https:\/\/doi.org\/10.1016\/j.gene.2017.04.027.","DOI":"10.1016\/j.gene.2017.04.027"},{"key":"2025110310023745384_j_znc-2024-0224_ref_005","doi-asserted-by":"crossref","unstructured":"Kciuk, M, Gieleci\u0144ska, A, Mujwar, S, Mojzych, M, Marciniak, B, Drozda, R, et al.. Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies. J Enzym Inhib Med Chem 2022;37:1278\u201398. https:\/\/doi.org\/10.1080\/14756366.2022.2052868.","DOI":"10.1080\/14756366.2022.2052868"},{"key":"2025110310023745384_j_znc-2024-0224_ref_006","doi-asserted-by":"crossref","unstructured":"Li, J, Zhang, G, Wang, X, Li, XF. Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia? Future Oncol 2015;11:1531\u201341. https:\/\/doi.org\/10.2217\/fon.15.11.","DOI":"10.2217\/fon.15.11"},{"key":"2025110310023745384_j_znc-2024-0224_ref_007","doi-asserted-by":"crossref","unstructured":"Pastorek, J, Pastorekova, S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin Cancer Biol 2015;31:52\u201364. https:\/\/doi.org\/10.1016\/j.semcancer.2014.08.002.","DOI":"10.1016\/j.semcancer.2014.08.002"},{"key":"2025110310023745384_j_znc-2024-0224_ref_008","doi-asserted-by":"crossref","unstructured":"Swietach, P, Patiar, S, Supuran, CT, Harris, AL, Vaughan-Jones, RD. The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem 2009;284:20299\u2013310. https:\/\/doi.org\/10.1074\/jbc.m109.006478.","DOI":"10.1074\/jbc.M109.006478"},{"key":"2025110310023745384_j_znc-2024-0224_ref_009","doi-asserted-by":"crossref","unstructured":"Kalinin, S, Malkova, A, Sharonova, T, Sharoyko, V, Bunev, A, Supuran, CT, et al.. Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors. Int J Mol Sci 2021;22. https:\/\/doi.org\/10.3390\/ijms222413405.","DOI":"10.3390\/ijms222413405"},{"key":"2025110310023745384_j_znc-2024-0224_ref_010","doi-asserted-by":"crossref","unstructured":"Campos, NSP, Souza, BS, Silva, GCP, Porto, VA, Chalbatani, GM, Lagreca, G, et al.. Carbonic anhydrase IX: a renewed target for cancer immunotherapy. Cancers 2022;14. https:\/\/doi.org\/10.3390\/cancers14061392.","DOI":"10.3390\/cancers14061392"},{"key":"2025110310023745384_j_znc-2024-0224_ref_011","doi-asserted-by":"crossref","unstructured":"Gaspari, R, Rechlin, C, Heine, A, Bottegoni, G, Rocchia, W, Schwarz, D, et al.. Kinetic and structural insights into the mechanism of binding of sulfonamides to human carbonic anhydrase by computational and experimental studies. J Med Chem 2016;59:4245\u201356. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01643.","DOI":"10.1021\/acs.jmedchem.5b01643"},{"key":"2025110310023745384_j_znc-2024-0224_ref_012","doi-asserted-by":"crossref","unstructured":"Dudutiene, V, Matulien\u0117, J, Smirnov, A, Timm, DD, Zubrien\u0117, A, Baranauskien\u0117, L, et al.. Discovery and characterization of novel selective inhibitors of carbonic anhydrase IX. J Med Chem 2014;57:9435\u201346. https:\/\/doi.org\/10.1021\/jm501003k.","DOI":"10.1021\/jm501003k"},{"key":"2025110310023745384_j_znc-2024-0224_ref_013","doi-asserted-by":"crossref","unstructured":"Khanfar, MA, Quinti, L, Wang, H, Choi, SH, Kazantsev, AG, Silverman, RB. Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors. Eur J Med Chem 2014;76:414\u201326. https:\/\/doi.org\/10.1016\/j.ejmech.2014.02.003.","DOI":"10.1016\/j.ejmech.2014.02.003"},{"key":"2025110310023745384_j_znc-2024-0224_ref_014","doi-asserted-by":"crossref","unstructured":"Khanfar, MA, Quinti, L, Wang, H, Nobles, J, Kazantsev, AG, Silverman, RB. Design and evaluation of 3-(benzylthio)benzamide derivatives as potent and selective SIRT2 inhibitors. ACS Med Chem Lett 2015;6:607\u201311. https:\/\/doi.org\/10.1021\/acsmedchemlett.5b00075.","DOI":"10.1021\/acsmedchemlett.5b00075"},{"key":"2025110310023745384_j_znc-2024-0224_ref_015","doi-asserted-by":"crossref","unstructured":"Khanfar, MA, Salaas, N, Abumostafa, R. Discovery of natural-derived M(pro) inhibitors as therapeutic candidates for COVID-19: structure-based pharmacophore screening combined with QSAR analysis. Mol Inform 2023:e2200198. https:\/\/doi.org\/10.1002\/minf.202200198.","DOI":"10.1002\/minf.202200198"},{"key":"2025110310023745384_j_znc-2024-0224_ref_016","doi-asserted-by":"crossref","unstructured":"Khanfar, MA, Banat, F, Alabed, S, Alqtaishat, S. Discovery of potent NEK2 inhibitors as potential anticancer agents using structure-based exploration of NEK2 pharmacophoric space coupled with QSAR analyses. Mol Divers 2017;21:187\u2013200. https:\/\/doi.org\/10.1007\/s11030-016-9696-5.","DOI":"10.1007\/s11030-016-9696-5"},{"key":"2025110310023745384_j_znc-2024-0224_ref_017","doi-asserted-by":"crossref","unstructured":"Khanfar, MA, Alqtaishat, S. Discovery of potent natural-product-derived SIRT2 inhibitors using structure- based exploration of SIRT2 pharmacophoric space coupled with QSAR analyses. Anti Cancer Agents Med Chem 2021;21:2278\u201386. https:\/\/doi.org\/10.2174\/1871520621666210112121523.","DOI":"10.2174\/1871520621666210112121523"},{"key":"2025110310023745384_j_znc-2024-0224_ref_018","doi-asserted-by":"crossref","unstructured":"Salassa, G, Terenzi, A. Metal complexes of oxadiazole ligands: an overview. Int J Mol Sci 2019;20. https:\/\/doi.org\/10.3390\/ijms20143483.","DOI":"10.3390\/ijms20143483"},{"key":"2025110310023745384_j_znc-2024-0224_ref_019","doi-asserted-by":"crossref","unstructured":"Benassi, A, Doria, F, Pirota, V. Groundbreaking anticancer activity of highly diversified oxadiazole scaffolds. Int J Mol Sci 2020;21. https:\/\/doi.org\/10.3390\/ijms21228692.","DOI":"10.20944\/preprints202011.0029.v1"},{"key":"2025110310023745384_j_znc-2024-0224_ref_020","doi-asserted-by":"crossref","unstructured":"Khanfar, MA. Oxadiazol-based mTOR inhibitors with potent antiproliferative activities: synthetic and computational modeling. Mol Divers 2022;26:3357\u201364. https:\/\/doi.org\/10.1007\/s11030-021-10367-4.","DOI":"10.1007\/s11030-021-10367-4"},{"key":"2025110310023745384_j_znc-2024-0224_ref_021","unstructured":"Alley, MC, Scudiero, DA, Monks, A, Hursey, ML, Czerwinski, MJ, Fine, DL, et al.. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589\u2013601."},{"key":"2025110310023745384_j_znc-2024-0224_ref_022","doi-asserted-by":"crossref","unstructured":"Khanfar, MA, Salman, IM, Ameer, OZ. Synthesis and biological evaluation of thiazole-based fibroblast growth factor receptor-1 inhibitors. Anti Cancer Agents Med Chem 2022. https:\/\/doi.org\/10.2174\/1871520622666220905141248.","DOI":"10.2174\/1871520622666220905141248"},{"key":"2025110310023745384_j_znc-2024-0224_ref_023","doi-asserted-by":"crossref","unstructured":"Shoemaker, RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813\u201323. https:\/\/doi.org\/10.1038\/nrc1951.","DOI":"10.1038\/nrc1951"}],"container-title":["Zeitschrift f\u00fcr Naturforschung C"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/znc-2024-0224\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/znc-2024-0224\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:06:20Z","timestamp":1762164380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/znc-2024-0224\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":23,"journal-issue":{"issue":"11-12","published-online":{"date-parts":[[2025,2,11]]},"published-print":{"date-parts":[[2025,11,25]]}},"alternative-id":["10.1515\/znc-2024-0224"],"URL":"https:\/\/doi.org\/10.1515\/znc-2024-0224","relation":{},"ISSN":["0939-5075","1865-7125"],"issn-type":[{"type":"print","value":"0939-5075"},{"type":"electronic","value":"1865-7125"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}